[A case of massive pancreatic neuroendocrine carcinoma successfully treated with surgical resection and postoperative everolimus administration].

Abstract

A 55-year-old woman presented to our hospital with a chief complaint of abdominal pain. Computed tomography (CT) revealed a massive tumor originating from the tail of the pancreas, with liver and lymph node metastasis. Percutaneous biopsy was performed and yielded a diagnosis of pancreatic neuroendocrine carcinoma. The patient underwent distal pancreatectomy, lateral segmentectomy of the liver, para-aortic lymph node dissection, and cytoreductive surgery for treatment of peritoneal dissemination. Octreotide was administered on post-operative day (POD) 3. Treatment with everolimus (10 mg/day) was initiated on POD 32. Stable disease according to the Response Evaluation Criteria in Solid Tumors( RECIST) was observed for 4 months, and the patient survived for a total of 9 months after surgery. Everolimus was tolerated safely and was effective for the treatment of pancreatic neuroendocrine carcinoma.

• Authors: Yosuke Mukai, Yutaka Takeda, Shin Nakahira, Yoshiteru Katsura, Hiroki Kusama, Naoyoshi Hashimoto, Katsunori Matsushita, Hiroshi Kawashima, Michiko Hamanaka, Yoshinori Kagawa, Atsushi Takeno, Masatsugu Okishiro, Hideki Sakisaka, Rei Suzuki, Chiyomi Egawa, Hirokazu Taniguchi, Takeshi Kato, Shigeyuki Tamura
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 40 Issue 12 Pg. 1887-9 (Nov 2013) ISSN: 0385-0684 [Print] Japan
• PMID: 24393955 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Antineoplastic Agents
• Everolimus
• Sirolimus

Topics

• Antineoplastic Agents (therapeutic use)
• Carcinoma, Neuroendocrine (drug therapy, surgery)
• Chemotherapy, Adjuvant
• Everolimus
• Fatal Outcome
• Female
• Humans
• Middle Aged
• Palliative Care
• Pancreatic Neoplasms (drug therapy)
• Sirolimus (analogs & derivatives, therapeutic use)